LPCN

4.37

1.80% -0.08

Handel nachbörslich: 4.45 0.08 +1.83%

Lipocine Inc (LPCN)

Überblick Nachrichten Preisverlauf Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$4.45

Offen:

$4.47

24-Stunden-Volumen:

42,027

Relative Volume:

1.43

Marktkapitalisierung:

$23.37M

Einnahmen:

Nettoeinkommen (Verlust:

$-16.35M

KGV:

-1.4328

EPS:

-3.05

Netto-Cashflow:

$-11.88M

1W Leistung:

-10.63%

1M Leistung:

-16.12%

6M Leistung:

-31.50%

1J Leistung:

+13.51%

1-Tages-Spanne:

$4.25

$4.5592

1-Wochen-Bereich:

$4.25

$4.889

52-Wochen-Spanne:

$3.20

$11.79

Lipocine Inc Stock (LPCN) Company Profile

Firmenname

Lipocine Inc

Sektor

Healthcare (1174)

Branche

Biotechnology (684)

Telefon

801 994 7383

Adresse

675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-11-06

Neueste SEC-Einreichungen

LPCN's Discussions on Twitter

Vergleichen Sie LPCN mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
LPCN Lipocine Inc	4.37	23.37M	0	-16.35M	-11.88M	-3.05
VRTX Vertex Pharmaceuticals Inc	422.00	108.68B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	681.58	74.90B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	640.52	38.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	246.27	31.76B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	111.93	26.83B	3.30B	-501.07M	1.03B	-2.1146

Lipocine Inc Stock (LPCN) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2021-06-24	Eingeleitet	Cantor Fitzgerald	Overweight
2020-12-10	Hochstufung	Ladenburg Thalmann	Neutral → Buy
2018-01-12	Bestätigt	H.C. Wainwright	Buy
2018-01-11	Herabstufung	Canaccord Genuity	Buy → Hold
2017-12-08	Fortgesetzt	H.C. Wainwright	Buy
2016-10-07	Eingeleitet	H.C. Wainwright	Buy
2015-07-22	Eingeleitet	ROTH Capital	Buy
2015-06-23	Eingeleitet	Canaccord Genuity	Buy

Alle ansehen

Lipocine Inc Aktie (LPCN) Neueste Nachrichten

02:10 AM

FDA Grants Fast Track Designation to Lipocine (NASDAQ:LPCN) for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis - Defense World

Dec 19, 2024

Dec 17, 2024

Lipocine Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits - Quantisnow

Dec 17, 2024

FDA fast tracks Lipocine's sarcopenia treatment - Investing.com

Dec 17, 2024

FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis - PR Newswire

Dec 17, 2024

FDA Grants Fast Track Designation to LPCN 1148 as Treatment for Sarcopenia - Contract Pharma

Dec 17, 2024

Dec 16, 2024

Lipocine (NASDAQ:LPCN) Now Covered by StockNews.com - Defense World

Dec 16, 2024

Dec 11, 2024

Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference - The Eastern Progress Online

Dec 11, 2024

Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session - The Eastern Progress Online

Dec 11, 2024

Where are the Opportunities in (LPCN) - Stock Traders Daily

Dec 11, 2024

Dec 06, 2024

Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024 - The Eastern Progress Online

Dec 06, 2024

Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference - The Eastern Progress Online

Dec 06, 2024

Nov 29, 2024

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024 - GuruFocus.com

Nov 29, 2024

Nov 25, 2024

Lipocine Announces Supply and Distribution Agreement with Pharma - GuruFocus.com

Nov 25, 2024

Nov 09, 2024

Lipocine (NASDAQ:LPCN) Announces Financial Results for the Quarter Ended September 30, 2024 - Defense World

Nov 09, 2024

Nov 08, 2024

When the Price of (LPCN) Talks, People Listen - Stock Traders Daily

Nov 08, 2024

Nov 07, 2024

Lipocine: Q3 Earnings Snapshot - CT Insider

Nov 07, 2024